UnitedHealth Group Q2 2026 Earnings: Profit Beats Expectations as Medical Costs Ease
UnitedHealth's Q2 profit beat estimates as medical costs eased, and the company raised its full-year profit outlook.
| Q2 2026 | Reported | Expected | Surprise |
|---|---|---|---|
| EPS | $6.38 | $4.95 | +28.8% |
| Revenue | $112.03B | $111.96B | +0.1% |
Key takeaways
- Adjusted profit per share came in well above what Wall Street had expected, while revenue landed roughly in line with forecasts — a sign the health insurer is stabilizing after a rough 2025 marked by rising medical costs.
- The company’s “medical cost ratio” — the share of premium dollars paid out to cover members’ medical care — fell to 86.7% from 89.4% a year earlier. A lower ratio means more of each premium dollar was kept rather than paid out in claims, which the company credited to tighter benefit design, pricing changes and cost-management efforts.
- Both major divisions contributed to the improvement: the UnitedHealthcare insurance business grew its earnings, while Optum, which handles pharmacy benefits, care delivery and health data services, expanded its profit margin by about 1.6 percentage points from a year ago.
- Management raised its full-year 2026 adjusted profit forecast to $19.50-$20.00 per share, up from a prior outlook of more than $18.25, while keeping full-year revenue guidance above $439 billion.
- The company also improved its full-year outlook for the medical cost ratio to about 88.1%, better than the 88.8% it had projected earlier this year — another signal that management expects cost pressures to keep easing through the rest of 2026.
- CEO Stephen Hemsley said the results and updated outlook reflect “continuing progress toward delivering more consistent and dependable performance,” pointing to efforts to simplify operations and improve affordability for patients and providers.
- The rebound follows a difficult stretch: over the trailing twelve months, per-share profit was still down sharply from the prior year, reflecting the medical-cost spike and other pressures that weighed on the company through 2025 — this quarter is an early sign of that trend easing rather than a complete turnaround.
Q2 2026 in context
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $112.0B | $111.6B | +0.4% |
| Net income | $5.5B | $3.4B | +61.0% |
| Free cash flow | $10.3B | $6.3B | +62.7% |
| Diluted EPS | $6.04 | $3.74 | +61.5% |
| Gross margin | 88.1% | 88.3% | -0.3 pts |
| Operating margin | 7.1% | 4.6% | +2.5 pts |
| Net margin | 4.9% | 3.1% | +1.8 pts |
Figures for the quarter ended Jun 2026 and the quarter ended Jun 2025, as reported to the SEC.
Each company's quarter ending in calendar Q2 '26, as reported to the SEC. A peer that reported no revenue figure for that quarter is left out.
How the stock took it
UnitedHealth Group Incorporated closed at $418.52 on Jul 15, 2026, the last session before the report, and at $426.09 on Jul 17, 2026, the first session after it — +1.8% across the report.
| Earlier report | Close before | Close after | Change |
|---|---|---|---|
| May 5, 2026 | $370.75 | $367.28 | -0.9% |
| Oct 28, 2025 | $365.98 | $355.26 | -2.9% |
| Aug 11, 2025 | $250.89 | $261.57 | +4.3% |
Closes from the market's daily record. Each figure spans the report date — from the last session that closed before it to the first that closed after — because a company may report before the open or after the close.
Sources: company report · earnings call